10-Q: IO Biotech Faces Going Concern Doubt After Cylembio's FDA Setback

IO Biotech reports substantial doubt about its ability to continue as a going concern, following the FDA's recommendation against a BLA submission for its lead cancer vaccine, Cylembio, despite promising Phase 3 PFS data.

Summary

• IO Biotech reported a net loss of $57.0 million for the nine months ended September 30, 2025, an improvement from $64.2 million in the prior year period.
• Cash and cash equivalents decreased significantly to $30.7 million as of September 30, 2025, from $60.0 million at December 31, 2024.
• The company has identified substantial doubt about its ability to continue as a going concern, with current cash expected to fund operations only through Q1 2026.
• The FDA recommended against submitting a Biologics License Application (BLA) for Cylembio (IO102-IO103) based on the IOB-013 Phase 3 trial data, which narrowly missed statistical significance for its primary endpoint of progression-free survival (PFS).
• The IOB-013 trial showed a median PFS of 19.4 months for Cylembio plus pembrolizumab versus 11.0 months for pembrolizumab alone, with a hazard ratio of 0.77 (p=0.056).
• IO Biotech announced a restructuring and workforce reduction plan on September 26, 2025, cutting approximately 50% of its headcount (34 people) to conserve capital, incurring $0.9 million in restructuring charges in Q3 2025.
• The company drew down €10.0 million (Tranche A) and €12.5 million (Tranche B) from its European Investment Bank (EIB) loan facility, but conditions for the €15.0 million Tranche C will not be met due to the IOB-013 trial results.
• Preliminary data from an investigator-initiated study of Cylembio plus nivolumab-relatlimab in advanced melanoma showed an early trend of improved clinical activity without additional systemic toxicity.
• Phase 2 basket trial (IOB-022/KN-D38) for Cylembio in NSCLC and SCCHN met its primary endpoint of overall response rate (ORR) in the SCCHN cohort (44.4%) and showed promising activity in the NSCLC cohort (48% confirmed ORR).
• Preclinical development continues for IO112 (Arginase 1-derived peptide vaccine) and IO170 (TGF-selective peptide vaccine), with IND filings anticipated in 2026 for both.
• A material weakness in internal control over financial reporting related to CRO accruals and prepayments remains un-remediated, with remediation expected by the end of fiscal year 2025.

Sentiment

Score: 2

Explanation: The sentiment is highly negative due to the FDA's recommendation against BLA submission for the lead candidate, Cylembio, which significantly delays its path to market. This, coupled with the explicit 'going concern' warning, substantial cash burn, and a 50% workforce reduction, indicates severe financial distress and significant operational challenges. While some preclinical and Phase 2 data show promise, the primary regulatory setback overshadows these positives.

Positives

• Net loss for the nine months ended September 30, 2025, decreased to $57.0 million from $64.2 million in the prior year, indicating a reduced rate of loss.
• The Phase 3 IOB-013 trial for Cylembio in advanced melanoma demonstrated a clinical improvement in median progression-free survival (PFS) of 19.4 months compared to 11.0 months for pembrolizumab alone, showing a positive trend.
• The combination therapy in the IOB-013 trial was well tolerated, with no increase in immune-mediated adverse events (34.0% vs 38.4%) or Grade 3 treatment-related events (14.5% vs 15.6%) compared to pembrolizumab alone.
• The Phase 2 IOB-022/KN-D38 basket trial met its primary endpoint of overall response rate (ORR) in the SCCHN cohort (44.4% confirmed ORR) and showed promising activity in the NSCLC cohort (48% confirmed ORR).
• Efficacy results from the SCCHN cohort of the IOB-022/KN-D38 trial satisfied a clinical condition precedent for the EIB Tranche B loan, allowing for a €12.5 million drawdown.
• Preliminary data from an investigator-initiated study of Cylembio plus nivolumab-relatlimab showed an early trend suggestive of improved clinical activity without additional systemic toxicity.
• Preclinical data for IO112 and IO170 demonstrated anti-tumor activity and modulation of the tumor microenvironment, supporting continued development.

Negatives

• The FDA recommended against submitting a Biologics License Application (BLA) for Cylembio based on the IOB-013 Phase 3 trial data, indicating a significant regulatory setback and extended timeline for U.S. approval.
• The primary endpoint of statistical significance for PFS in the IOB-013 Phase 3 trial was narrowly missed (p=0.056, threshold p<0.045).
• Cash and cash equivalents significantly decreased to $30.7 million as of September 30, 2025, from $60.0 million at December 31, 2024.
• The company has concluded that conditions raise substantial doubt about its ability to continue as a going concern for one year after the financial statements are issued.
• Existing cash and cash equivalents are expected to be sufficient only through the first quarter of 2026, necessitating additional capital.
• A restructuring and workforce reduction plan was implemented, cutting approximately 50% of the company's headcount (34 people), indicating financial strain.
• Conditions for drawing down the €15.0 million Tranche C of the EIB loan facility will not be met due to the IOB-013 Phase 3 trial results, limiting access to potential funding.
• A material weakness in internal control over financial reporting related to CRO accruals and prepayments remains un-remediated, posing risks to financial reporting reliability.

Risks

• Substantial doubt about the company's ability to continue as a going concern due to recurring losses and insufficient cash to fund operations for at least 12 months.
• Inability to obtain additional capital on a timely basis or favorable terms, which could lead to significant delays, scaling back, or discontinuation of research and development programs.
• Failure to obtain regulatory approval for Cylembio or other product candidates, or significant delays in doing so, particularly after the FDA's recommendation against BLA submission for Cylembio.
• Preclinical and clinical trials may fail to sufficiently demonstrate safety and efficacy, or identify serious adverse side effects, preventing or limiting regulatory approval.
• Reliance on third-party suppliers and contract manufacturing organizations (CMOs) for product candidate manufacturing, which can lead to production difficulties, delays, or supply interruptions.
• Intense competition from other pharmaceutical and biotechnology companies, many with greater financial resources and expertise, potentially leading to competitors developing or commercializing products more quickly or successfully.
• Inability to obtain and maintain sufficient intellectual property protection for platform technologies and product candidates, or if the scope of protection is not broad enough, allowing competitors to develop similar products.
• Exposure to significant foreign exchange risk due to operations in Denmark and expenses/revenues in various currencies.
• Potential product liability claims if product candidates harm patients or are perceived to harm patients, leading to substantial liability and costs.
• Difficulty in retaining key members of senior management and attracting, retaining, and motivating qualified personnel.
• Challenges in managing growth as the company expands its clinical development and regulatory capabilities, potentially disrupting operations.
• Unfavorable pricing regulations or third-party coverage and reimbursement policies, making it difficult to sell product candidates profitably if approved.
• Smaller than anticipated market opportunities for product candidates, adversely affecting revenue.
• Inability to establish sales and marketing capabilities or enter into agreements with third parties to commercialize product candidates if approved.
• Risk of substantial fines, criminal penalties, or other enforcement actions if determined to be promoting products for unapproved or off-label uses.
• Failure to obtain approval or commercialize products in jurisdictions outside the U.S. and EU, limiting market potential.
• Minimal or no control over the conduct of investigator-initiated clinical trials, which could negatively impact development programs.
• Delays or difficulties in clinical trial site activations and patient enrollment/retention.
• Interim, preliminary, and top-line clinical trial results may change as more data becomes available, potentially harming business prospects.
• Regulatory approval processes are lengthy, time-consuming, and inherently unpredictable.
• Product candidates based on novel technologies may not gain broad acceptance among doctors or patients.
• Changes in product candidate manufacturing or formulation may result in additional costs or delays.
• Challenges from tax authorities regarding transfer pricing procedures or the corporate reorganization.
• Limitations on the ability to utilize net operating losses and other deferred tax assets due to insufficient future taxable income or ownership changes.
• Exposure to current taxation on income of foreign subsidiaries (CFC rules) even without cash distributions.
• Non-compliance with federal and state healthcare fraud and abuse laws, transparency laws, and other healthcare laws and regulations.
• Impact of healthcare legislative reform measures (e.g., ACA, IRA, MFN pricing) on business and results of operations.
• Upcoming changes in EU pharmaceutical product legislation potentially reducing data and market exclusivity.
• Failure to comply with privacy and data security laws, leading to regulatory investigations, reputational damage, or fines.
• Vulnerability of internal information technology systems and those of third-party contractors to failures, security breaches, or data loss.
• Adverse effects from global economic and political instability and conflicts (e.g., Ukraine, Middle East affecting Israeli clinical sites).
• Disruptions from natural disasters, terrorism, or public health emergencies.
• Violations of U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions, and other trade laws and regulations.
• Securities class action litigation following stock price declines.
• Inability to maintain Nasdaq listing due to minimum bid price or other requirements.
• Delaware law and corporate provisions could make mergers or tender offers difficult.
• Future sales and issuances of common stock or exercise of warrants could dilute existing stockholders and cause stock price to fall.
• Reduced disclosure requirements as an emerging growth company and smaller reporting company may make common shares less attractive to investors.
• Increased costs and management time devoted to compliance as a public company.
• Failure to build finance infrastructure and improve accounting systems and controls.
• Changes in financial accounting standards or practices causing adverse revenue fluctuations.
• Changes in tax laws or regulations adversely affecting the business.
• Management's broad discretion in using cash and cash equivalents may not increase share value.
• Failure to meet evolving investor, stakeholder, and governmental expectations regarding environmental, social, and corporate governance (ESG) matters.
• Impact of judicial challenges to regulatory policy (e.g., *Chevron* deference) on the biopharmaceutical industry.

Future Outlook

The company expects operating losses and negative cash flows to continue for the foreseeable future as it develops product candidates. Current cash and cash equivalents are projected to fund operations only through the first quarter of 2026, necessitating additional capital. Overall survival (OS) results for the IOB-013 Phase 3 trial are projected to be available in 2026. The company plans to meet with the FDA in December 2025 to align on the design of a potential new registrational study for Cylembio and will discuss IOB-013 data with European regulators to determine a path for EU submission. IND filings for IO112 and continued IND-enabling studies for IO170 are anticipated in 2026. The company is implementing a restructuring plan to conserve capital while pursuing regulatory approval pathways and completing ongoing studies.

Management Comments

• "We currently expect that our cash and cash equivalents of $30.7 million as of September 30, 2025 will not be sufficient to fund our operating expenses and capital requirements for at least 12 months from the date the financial statements are issued."
• "The Company has been actively seeking, and continues to actively seek, additional capital, including through public or private equity or debt financing, strategic collaborations, strategic collaborations, licensing and other arrangements to fulfill its operating and capital requirements for the next 12 months."
• "Management has concluded that the aforementioned conditions, among others, raise substantial doubt about the Companys ability to continue as a going concern for one year after the date the financial statements are issued."
• "The Company plans to continue the dialogue with FDA to align on the design of a potential new registrational study for Cylembio."
• "The Company also plans to discuss the data from the IOB-013 clinical trial with European regulators."
• "The Company is restructuring to reduce the Companys ongoing expense structure and incurred a non-recurring charge of $0.9 million in the third quarter of 2025 related to the restructuring, which includes an approximate 50% percent reduction in full-time employees."

Industry Context

The biopharmaceutical industry, particularly immuno-oncology, is highly competitive and capital-intensive. IO Biotech's T-win platform represents a novel approach to therapeutic cancer vaccines, targeting immunosuppressive mechanisms. The FDA's recommendation against a BLA submission for Cylembio, despite positive PFS trends, highlights the stringent regulatory hurdles and the high bar for statistical significance in late-stage oncology trials, especially in combination with established therapies like KEYTRUDA. The ongoing development of other candidates like IO112 and IO170 reflects the industry's continuous pursuit of diverse targets within the tumor microenvironment. The workforce reduction and going concern warning underscore the financial pressures faced by clinical-stage companies when lead candidates encounter regulatory setbacks, a common challenge in this high-risk, high-reward sector. The mention of competitors like Amgen, AstraZeneca, BMS, Merck, Novartis, Pfizer, Moderna, Regeneron, Roche, Iovance, and Shenzhen emphasizes the crowded landscape for melanoma and other cancer treatments.

Comparison to Industry Standards

• The Phase 3 IOB-013 trial's median PFS of 19.4 months for Cylembio plus pembrolizumab compared to 11.0 months for pembrolizumab alone shows a substantial numerical improvement, but narrowly missing statistical significance (p=0.056 vs. threshold p<0.045) is a critical regulatory hurdle. For context, other anti-PD-1 monotherapies like pembrolizumab (KEYTRUDA) and nivolumab (Opdivo) have established strong benchmarks in first-line advanced melanoma, with reported median PFS values varying but generally in the range of 7-12 months for monotherapy, and higher for combination therapies (e.g., nivolumab + ipilimumab). The observed PFS for Cylembio combination is numerically competitive with some established combination therapies, but the lack of statistical significance against pembrolizumab monotherapy is a key differentiator.
• The safety profile of Cylembio in combination with pembrolizumab, showing no additional systemic toxicity compared to pembrolizumab monotherapy, is a positive aspect, aligning with industry goals for improved tolerability in combination regimens. This is comparable to the safety profiles seen with other checkpoint inhibitor combinations where the added agent does not significantly increase severe adverse events.
• The 44.4% confirmed ORR in the SCCHN cohort of the Phase 2 IOB-022/KN-D38 trial compares favorably to the pembrolizumab monotherapy benchmark of 23% from the Keynote-048 study. Similarly, the 48% confirmed ORR in the NSCLC cohort compares well against the Keynote-042 study's 39% benchmark for pembrolizumab monotherapy. These Phase 2 results suggest competitive activity in these indications, although they are not from registrational trials.
• The company's 'substantial doubt about going concern' status and significant cash burn rate are below industry standards for financial stability, especially for a company with a lead candidate facing regulatory delays. Many clinical-stage biotechs maintain a longer cash runway (e.g., 18-24 months) to navigate development uncertainties.
• The workforce reduction of approximately 50% is a drastic measure, indicating a more severe financial situation than typically seen in companies with promising mid-stage assets, even after a Phase 3 setback. This level of reduction is usually reserved for companies facing significant pipeline failures or strategic shifts.

Corporate Governance

Legal Proceedings

• No material legal proceedings were subject to during the nine months ended September 30, 2025, and none are currently pending or threatened.

Related Party Transactions

• In the August 2023 Private Placement, legal entities of certain related parties contributed $33.4 million, and members of management contributed $0.2 million.

Stakeholder Impact

• **Shareholders:** Significant dilution risk from potential future equity raises, potential loss of investment due to 'going concern' doubt, and stock price volatility due to regulatory setbacks and financial instability.
• **Employees:** Approximately 50% of the workforce (34 people) were impacted by a reduction-in-force, leading to job losses and potential morale issues for remaining staff.
• **Creditors (EIB):** The company has drawn down on Tranche A and B of the EIB loan, but the failure to meet Tranche C conditions and the overall financial uncertainty increase credit risk.
• **Patients:** Delays in regulatory approval for Cylembio in the U.S. mean patients will have to wait longer for potential access to this therapeutic option.
• **Clinical Trial Sites/CROs:** The workforce reduction and financial constraints may impact the company's ability to fund and manage ongoing and future clinical trials, potentially affecting partners and investigators.

Next Steps

• Schedule and conduct a meeting with the FDA in December 2025 to align on the design of a potential new registrational study for Cylembio in patients with advanced melanoma.
• Discuss the IOB-013 clinical trial data with European regulators to determine a path to submission in the EU.
• Actively seek additional capital through public or private equity or debt financing, strategic collaborations, licensing, and other arrangements.
• Complete the execution of the restructuring plan, including the workforce reduction, by the end of the fourth quarter of 2025.
• Remediate the material weakness in internal control over financial reporting related to CRO accruals and prepayments by the end of fiscal year 2025.
• Anticipate filing an Investigational New Drug (IND) application for IO112 in 2026.
• Continue IND-enabling studies for IO170 in 2026.
• Present data from the Phase 2 IOB-032/PN-E40 basket trial at medical meetings in 2026.
• Await overall survival (OS) results from the IOB-013 Phase 3 trial, projected to be available in 2026.

Key Dates

Recommendation

The filing presents a highly concerning outlook. The explicit 'substantial doubt about the Company's ability to continue as a going concern' is a critical red flag, indicating severe financial instability. This is compounded by the FDA's recommendation against a BLA submission for Cylembio, the company's lead candidate, which effectively halts its near-term path to market in the U.S. and necessitates a costly, time-consuming new registrational study. The significant cash burn, limited cash runway (through Q1 2026), and a drastic 50% workforce reduction further underscore the dire financial situation. While some Phase 2 data and preclinical results show promise, they are insufficient to offset the immediate and profound challenges related to regulatory approval and liquidity. Investors face substantial risk of capital loss, and the company's ability to fund future operations is highly uncertain.

Keywords

IO Biotech, IOBT, Cylembio, IO102-IO103, cancer vaccine, melanoma, Phase 3 trial, FDA BLA, regulatory setback, going concern, cash burn, workforce reduction, biopharmaceutical, T-win platform, immuno-oncology, clinical trials, financial results, Nasdaq, EIB loan, IO112, IO170, preclinical development, internal controls, risk factors